Heparin Calcium Market Size to Exceed USD 1,789.4 Mn by 2032

The Heparin Calcium Market, estimated at USD 1,485.0 Mn in 2025, is expected to exhibit a CAGR of 2.7% and reach USD 1,789.4 Mn by 2032.

The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.

Increasing prevalence atrial fibrillation is expected to drive the global heparin calcium market over the forecast period. For instance, in January 2025, according to the data published in BMJ Journal, a survey was conducted among 47,841 adults in seven geographic regions of China in 2025. It was stated that the atrial fibrillation prevalence increased from 0.8% to 5.4% in the age group of 45-54 years and 0.6% to 4.9% in the age group ≥75 years. Hence, it was concluded that the prevalence of atrial fibrillation is higher in China.

Global Heparin Calcium Market– Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic and consequent lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdowns in several regions. Private healthcare is one such sector that has been significantly impacted by the COVID-19 pandemic.

Many patients with COVID-19 have a severe respiratory infection that requires hospitalization and mechanical ventilation. Governments of various countries are focusing on initiatives to fight against the COVID-19 pandemic and stop the spread of the coronavirus infection by implementing various measures in the countries. Moreover, the governments of various countries have collaborated with  universities around the globe to find novel treatments option for COVID-19 and its related complications. For instance, according to the data published in National Center for Biotechnology Information, in August 2025. Coagulation activation has been reported in COVID-19 which increased the risk of pulmonary embolism, deep vein thrombosis, etc. Hence, low-molecular-weight or unfractionated heparin administration can benefit patients with COVID-19, due to its  anticoagulant effect to reduce the chances of pulmonary embolism.

Global Heparin Calcium Market: Key Developments

Increasing prevalence of pulmonary embolism among the patients is expected to drive the global heparin calcium market over the forecast period. For instance, according to the data published in The Jornal of the American Medical Association, in January 2025, a cross-sectional study was conducted in 7 French hospitals among 740 patients. Hence, it was stated that pulmonary embolism was detected in 5.9% of patients using a predefined diagnostic algorithm.

Browse 44 Market Data Tables and 38 Figures spread through 180 Pages and in-depth TOC on “Global Heparin Calcium Market”- Forecast to 2032, Global Heparin Calcium Market, Global Heparin Calcium Market, by Type (Unfractionated Heparin and Low Molecular Weight Heparin), by Route of Administration (Intravenous and Subcutaneous), by Application (Kidney Dialysis, Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Others (Cardiac Surgery, etc.)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/heparin-calcium-market-5483

Increasing awareness by key market players is expected to drive the global heparin calcium market over the forecast period. For instance, in March 2025, Cardinal Health, a healthcare company, announced that they had organized an awareness program to raise awareness about pulmonary embolism and deep vein thrombosis.As according to the national survey conducted in the U.S.found that 74% of adults had a poor knowledge of deep vein thrombosis, this awareness program will help the people about the management and prevention of deep vein thrombosis andpulmonary embolism.

Key Takeaways of the Global Heparin Calcium Market:

• The global heparin calcium market is expected to exhibit a CAGR of 2.7% during the forecast period, due to the increasing adoption of inorganic strategies such as product launch by key market players over the forecast period. For instance, in October 2025, Metabolon, Inc., a health technology company, announced that they had launched a new SmartPanel portfolio. SmartPanel solutions provide drug discovery and precision medicine researchers with a novel, dynamic process to explore biologically relevant views of metabolomic data in the context of specific metabolic pathways, biological themes, and disease associations.
• Among application, deep vein thrombosis is estimated to hold a dominant position in the global heparin calcium market over the forecast period due to the increasing launch of awareness campaign by key market players. For instance, in March 2025, The National Blood Clot Alliance (NBCA) announced that they had launched an awareness campaign to build an awareness among people about the increased risk of deep vein thrombosis.
• Among regions, Europe is estimated to account for the largest market share in the global heparin calcium market over the forecast period, owing to the increasing launch of awareness campaign by various organizations such as North America Thrombosis Forum. For instance, in April 2025, North America Thrombosis Forum, announced that they had taken an initiative to raise awareness about deep vein thrombosis by launching an awareness campaign. The aim of this camapaign is to aware people about the diagnosis and treatment of deep vein thromboisis.
• Major players operating in the global heparin calcium market include Sanofi, Pfizer Inc., Dongying Tiandong Pharmaceutical Co., Ltd., PANPHARMA S.A., Merck KGaA, Teva Pharmaceutical Industries Ltd., SMITHFIELD BIOSCIENCE, Afine Chemicals Limited, Yino Pharma Limited, Shandong Sheelian Pharmaceutical Co., Ltd., Aspen Holdings, Opocrin S.p.A.